Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation

Xinyi Zhou; Nan Jin; Baoan Chen

doi:10.3892/ol.2021.12579

Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation

Oncol Lett. 2021 Apr;21(4):318. doi: 10.3892/ol.2021.12579. Epub 2021 Feb 23.

Authors

Xinyi Zhou¹, Nan Jin¹, Baoan Chen¹

Affiliation

¹ Department of Hematology and Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu 210009, P.R. China.

Abstract

Cytomegalovirus (CMV) is an opportunistic virus, whereby recipients are most susceptible following allogeneic hematopoietic stem cell transplantation (allo-HSCT). With the development of novel immunosuppressive agents and antiviral drugs, accompanied with the widespread application of prophylaxis and preemptive treatment, significant developments have been made in transplant recipients with human (H)CMV infection. However, HCMV remains an important cause of short- and long-term morbidity and mortality in transplant recipients. The present review summarizes the molecular mechanism and risk factors of HCMV reactivation following allo-HSCT, the diagnosis of CMV infection following allo-HSCT, prophylaxis and treatment of HCMV infection, and future perspectives. All relevant literature were retrieved from PubMed and have been reviewed.

Keywords: CMV; allo-HSCT; cellular immunotherapy; hematological malignancy; preemptive treatment; prophylaxis.

Publication types

Review

Grants and funding

The present review was supported by the Natural Science Foundation of Jiangsu Province (grant no. BK20150639), the Key Medical of Jiangsu Province (grant no. ZDXKB2016020), the Six Talent Peaks Project in Jiangsu Province (grant no. WSW-033) and the Innovative and entrepreneurial doctors of Jiangsu province.